Skip Navigation

European Journal of Heart Failure 2007 9(2):173-177; doi:10.1016/j.ejheart.2006.05.010
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Perik, P. J.
Right arrow Articles by van Veldhuisen, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perik, P. J.
Right arrow Articles by van Veldhuisen, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society of Cardiology

Serum HER2 levels are increased in patients with chronic heart failure

Patrick J. Perika,b, Elisabeth G.E. de Vriesb, Jourik A. Gietemab, Winette T.A. van der Graafb, Tom D.J. Smildea, Dirk T. Sleijferb and Dirk J. van Veldhuisena,*

a Department of Cardiology, Thorax Center, University of Groningen and University Medical Center Groningen P.O. Box 30 001, 9700 RB Groningen, The Netherlands
b Department of Medical Oncology of the University of Groningen and University Medical Center Groningen The Netherlands

* Corresponding author. Tel.: +31 50 361 6161; fax: +31 50 361 4391. E-mail address: d.j.van.veldhuisen{at}thorax.umcg.nl


  Abstract

Background: The use of trastuzumab, an antibody against the human epidermal growth factor receptor 2 (HER2), in patients with HER2 positive metastatic breast cancer, is related to cardiotoxicity.

Aims: To investigate whether serum HER2 is increased in heart failure patients and related to disease severity.

Methods: Serum HER2, plasma tumor necrosis factor (TNF)-{alpha} and its soluble (s) receptors (sTNF-R1 and 2) were determined with ELISA in chronic heart failure patients and age and gender-matched healthy controls.

Results: Serum HER2 was higher (P=0.013) in 50 heart failure patients (18 female; median age 57 (range 33–77) years), mean 12.1±S.D. 2.3 ng/mL, than in 15 controls, 10.4±2.6 ng/mL. Serum HER2 levels correlated inversely with left ventricular ejection fraction (P=0.037) and were highest among NYHA class III patients, followed by NYHA class II patients and controls (P=0.029, Kruskal–Wallis test). STNF-R1 (P<.001) and sTNF-R2 (P=0.015) were higher in patients than controls, and correlated positively with HER2 (P=0.027 and P=0.036, respectively).

Conclusions: Serum HER2 levels are increased in chronic heart failure patients. Further research is necessary to determine whether HER2 plays a role in the pathophysiology of heart failure.

Key Words: HER2 • Heart failure • Cytokine • Cardiotoxicity • Trastuzumab

Received February 5, 2006; Revised April 17, 2006; Accepted May 18, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
B. Ky, S. E. Kimmel, R. N. Safa, M. E. Putt, N. K. Sweitzer, J. C. Fang, D. B. Sawyer, and T. P. Cappola
Neuregulin-1{beta} Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure
Circulation, July 28, 2009; 120(4): 310 - 317.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.